Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zhou, Z.
Right arrow Articles by Vollrath, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, Z.
Right arrow Articles by Vollrath, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 8, 2221-2228, Copyright © 1999 by Oxford University Press

ARTICLES

A cellular assay distinguishes normal and mutant TIGR/myocilin protein

Z Zhou and D Vollrath
Department of Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Lane Building, Room L305, Stanford, CA 94305-5120, USA

Glaucoma is a blinding eye disease that affects ~70 000 000 people world-wide. Mutations in the gene TIGR / MYOC have been shown to cause the most common form of the disease, primary open angle glaucoma, in selected families. Amino acid sequence variants of the gene have been found in 2-4% of sporadic primary open angle glaucoma cases. Most variants are rare and it is often difficult to definitively distinguish between a deleterious mutation and a benign variant solely on the basis of relative frequencies in patient and control groups. The function of the TIGR/myocilin protein is unknown and an assay to functionally classify variants is lacking. We sought to develop a biochemical assay to distinguish different forms of TIGR/myocilin. We investigated the Triton X-100 detergent solubility characteristics of mutant and normal forms of the protein, expressed by transfection in cultured cells. We observed a clear difference in the behavior of the two types of TIGR/myocilin; all confirmed mutant proteins tested were substantially Triton insoluble, while normal protein and controls were completely soluble. We also tested seven ambiguous variant proteins and classified them as mutant or normal on the basis of their Triton solubility. The results in some cases validated, and in other cases contradicted, earlier classifications of these variants. To our knowledge, Triton solubility is the first example of a general difference in the properties of mutant and normal forms of TIGR/myocilin. The assay we have developed will be useful for discerning protein functional information from the location of mutations, will aid genetic counseling of individuals with TIGR/myocilin variants and may provide a clue to understanding a mechanism by which mutations in TIGR / MYOC cause glaucoma.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
L.-Y. Jia, B. Gong, C.-P. Pang, Y. Huang, D. S.-C. Lam, N. Wang, and G. H.-F. Yam
Correction of the Disease Phenotype of Myocilin-Causing Glaucoma by a Natural Osmolyte
Invest. Ophthalmol. Vis. Sci., August 1, 2009; 50(8): 3743 - 3749.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
Y. H. Kwon, J. H. Fingert, M. H. Kuehn, and W. L.M. Alward
Primary Open-Angle Glaucoma
N. Engl. J. Med., March 12, 2009; 360(11): 1113 - 1124.
[Full Text] [PDF]

Home page
 Arch OphthalmolHome page
F. W. Rozsa, K. Scott, H. Pawar, S. Moroi, and J. E. Richards
Effects of Timolol on MYOC, OPTN, and WDR36 RNA Levels
Arch Ophthalmol, January 1, 2008; 126(1): 86 - 93.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
G. H.-F. Yam, K. Gaplovska-Kysela, C. Zuber, and J. Roth
Sodium 4-Phenylbutyrate Acts as a Chemical Chaperone on Misfolded Myocilin to Rescue Cells from Endoplasmic Reticulum Stress and Apoptosis
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1683 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. R. Shepard, N. Jacobson, J. C. Millar, I.-H. Pang, H. T. Steely, C. C. Searby, V. C. Sheffield, E. M. Stone, and A. F. Clark
Glaucoma-causing myocilin mutants require the Peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure
Hum. Mol. Genet., March 15, 2007; 16(6): 609 - 617.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. W. Hewitt, S. L. Bennett, J. H. Fingert, R. L. Cooper, E. M. Stone, J. E. Craig, and D. A. Mackey
The Optic Nerve Head in Myocilin Glaucoma
Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 238 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. L. Wiggs
Genetic Etiologies of Glaucoma
Arch Ophthalmol, January 1, 2007; 125(1): 30 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
A. W. Hewitt, S. L. Bennett, J. E. Richards, D. P. Dimasi, A. P. Booth, C. Inglehearn, R. Anwar, T. Yamamoto, J. H. Fingert, E. Heon, et al.
Myocilin Gly252Arg Mutation and Glaucoma of Intermediate Severity in Caucasian Individuals
Arch Ophthalmol, January 1, 2007; 125(1): 98 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
S. L. Bennett, A. W. Hewitt, J. L. Poulsen, L. S. Kearns, J. E. Morgan, J. E. Craig, and D. A. Mackey
Screening for Glaucomatous Disc Changes Prior to Diagnosis of Glaucoma in Myocilin Pedigrees
Arch Ophthalmol, January 1, 2007; 125(1): 112 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. H.-F. Yam, K. Gaplovska-Kysela, C. Zuber, and J. Roth
Aggregated Myocilin Induces Russell Bodies and Causes Apoptosis: Implications for the Pathogenesis of Myocilin-Caused Primary Open-Angle Glaucoma
Am. J. Pathol., January 1, 2007; 170(1): 100 - 109.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. D. Aroca-Aguilar, F. Sanchez-Sanchez, S. Ghosh, M. Coca-Prados, and J. Escribano
Myocilin Mutations Causing Glaucoma Inhibit the Intracellular Endoproteolytic Cleavage of Myocilin between Amino Acids Arg226 and Ile227
J. Biol. Chem., June 3, 2005; 280(22): 21043 - 21051.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Gobeil, M.-A. Rodrigue, S. Moisan, T. D. Nguyen, J. R. Polansky, J. Morissette, and V. Raymond
Intracellular Sequestration of Hetero-oligomers Formed by Wild-Type and Glaucoma-Causing Myocilin Mutants
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3560 - 3567.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
Y. Liu and D. Vollrath
Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma
Hum. Mol. Genet., June 1, 2004; 13(11): 1193 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
D. A. Mackey, D. L. Healey, J. H. Fingert, M. A. Coote, T. L. Wong, C. H. Wilkinson, P. J. McCartney, J. L. Rait, A. P. de Graaf, E. M. Stone, et al.
Glaucoma Phenotype in Pedigrees With the Myocilin Thr377Met Mutation
Arch Ophthalmol, August 1, 2003; 121(8): 1172 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Sohn, W. Hur, M. K. Joe, J.-H. Kim, Z.-W. Lee, K.-S. Ha, and C. Kee
Expression of Wild-Type and Truncated Myocilins in Trabecular Meshwork Cells: Their Subcellular Localizations and Cytotoxicities
Invest. Ophthalmol. Vis. Sci., December 1, 2002; 43(12): 3680 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
C. P. Pang, Y. F. Leung, B. Fan, L. Baum, W. C. Tong, W. S. Lee, J. K. H. Chua, D. S. P. Fan, Y. Liu, and D. S. C. Lam
TIGR/MYOC Gene Sequence Alterations in Individuals with and without Primary Open-Angle Glaucoma
Invest. Ophthalmol. Vis. Sci., October 1, 2002; 43(10): 3231 - 3235.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Torrado, R. Trivedi, R. Zinovieva, I. Karavanova, and S. I. Tomarev
Optimedin: a novel olfactomedin-related protein that interacts with myocilin
Hum. Mol. Genet., May 16, 2002; 11(11): 1291 - 1301.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
M. L. Green and T. E. Klein
A Multidomain TIGR/Olfactomedin Protein Family with Conserved Structural Similarity in the N-terminal Region and Conserved Motifs in the C-terminal Region
Mol. Cell. Proteomics, May 1, 2002; 1(5): 394 - 403.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. L. Wiggs and D. Vollrath
Molecular and Clinical Evaluation of a Patient Hemizygous for TIGR/MYOC
Arch Ophthalmol, November 1, 2001; 119(11): 1674 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. P. Fautsch and D. H. Johnson
Characterization of Myocilin-Myocilin Interactions
Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2324 - 2331.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
N. Jacobson, M. Andrews, A. R. Shepard, D. Nishimura, C. Searby, J. H. Fingert, G. Hageman, R. Mullins, B. L. Davidson, Y. H. Kwon, et al.
Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor
Hum. Mol. Genet., January 1, 2001; 10(2): 117 - 125.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. T. O’Brien, X.-o. Ren, and Y. Wang
Localization of Myocilin to the Golgi Apparatus in Schlemm's Canal Cells
Invest. Ophthalmol. Vis. Sci., November 1, 2000; 41(12): 3842 - 3849.
[Abstract] [Full Text]

Home page
 IOVSHome page
R. E. Swiderski, J. L. Ross, J. H. Fingert, A. F. Clark, W. L. M. Alward, E. M. Stone, and V. C. Sheffield
Localization of MYOC Transcripts in Human Eye and Optic Nerve by In Situ Hybridization
Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3420 - 3428.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.